Aclara to Present at Needham Third Annual Biotechnology Conference

Jun 10, 2004, 01:00 ET from ACLARA BioSciences

    MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- ACLARA
 BioSciences (Nasdaq:   ACLA) announced today that Thomas G. Klopack, ACLARA's
 chief executive officer will present at the Needham Third Annual Biotechnology
 Conference on Thursday, June 17, 2004 at 8:30 a.m. EDT at the Palace Hotel in
 New York.
     About ACLARA
     Founded in 1995, ACLARA is a biotechnology company working to provide
 physicians and researchers products and services to make personalized medicine
 a reality through its protein-based assay technology -- the eTag(TM) System.
 ACLARA is dedicated to unlocking the power of pathway biology to accelerate
 the development of next-generation targeted therapeutics, recognizing the most
 appropriate patients for approved therapies and identifying the
 highly-specific, protein-based biomarkers that will enable physicians to
 create truly personalized treatment regimens for patients suffering from
 cancer and other life-threatening disorders.
     ACLARA is commercializing its proprietary eTag System to enhance and
 accelerate drug discovery research and the preclinical and clinical
 development of targeted therapeutics.  ACLARA's technology may also enable the
 development of highly-specific, protein-based diagnostics capable of providing
 physicians with a powerful tool for creating personalized treatment regimens
 for patients suffering from serious and difficult-to-treat cancers.  For more
 information on ACLARA please visit the Company's web site at
     Forward-Looking Statements
     All statements in this news release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934 as amended. Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for ACLARA from those
 projected.  Those factors include risks and uncertainties relating to the
 performance of our products, anticipated progress in commercialization of our
 eTag(TM) assay system; the potential for use of our eTag assays in clinical
 development programs; the potential for use of our eTag assays as diagnostic
 tests; our ability to successfully conduct clinical studies and the results
 obtained from those studies; our ability to establish reliable, high-volume
 operations at commercially reasonable costs; expected reliance on a few
 customers for the majority of our revenues; actual market acceptance of our
 products and adoption of our technological approach and products by
 pharmaceutical and biotechnology companies; our estimate of the size of our
 markets; our estimates of the levels of demand for our products; our ability
 to develop organizational capabilities suitable for the further development
 and commercialization of our eTag assays; the ultimate validity and
 enforceability of our patent applications and patents; the possible
 infringement of the intellectual property of others; technological approaches
 of ACLARA and our competitors; our pending merger with ViroLogic, Inc.,
 including the risk that the closing conditions or the merger may not be
 satisfied and the merger may not be completed, and costs related to the
 proposed merger; and other risk factors identified in our Form 10-Q for the
 quarter ended March 31, 2004 as filed with the Securities and Exchange
     NOTE:  ACLARA BioSciences is a registered trademark, and eTag and the
 ACLARA logo are trademarks of ACLARA BioSciences, Inc.